Results 131 to 140 of about 19,083 (252)
, 2015 Alberto Migliore,1 Emanuele Bizzi,1 Colin Gerard Egan,2 Mauro Bernardi,3 Lea Petrella4 1Rheumatology Unit, San Pietro Fatebenefratelli Hospital, Rome, 2Primula Multimedia SRL, Pisa, 3Department of Statistical Sciences, University of Padova, Padova ...
Petrella L +4 more
core
, 1995 Bibliography: leaves 172-185.xii, 185 leaves : ill. ; 30 cm.Investigates the induction of heat shock protein (HSP) by some of the anti-inflammatory agents and antirheumatic agents used in the management of rheumatoid arthritis.
Burgiel, George
core
Health Science Reports, Volume 9, Issue 6, June 2026.ABSTRACT Background Inflammatory pain is a widespread global health concern arising from complex molecular pathways triggered by a consequence of tissue damage and immune activation. It significantly impacts quality of life and functional outcomes, necessitating a comprehensive understanding of underlying mechanisms and multidisciplinary approaches for
Fatma Mohamed Elmansy +6 more
wiley +1 more source
Journal of Arrhythmia, Volume 42, Issue 3, June 2026.COVID‐19 was associated with a sustained increase in device implantation and arrhythmia‐related interventions over 2 years. In a nationwide propensity score‐matched cohort, risks of pacemaker, ICD, CRT implantation, ablation procedures, and antiarrhythmic medication initiation remained higher after COVID‐19, supporting long‐term cardiovascular ...
Daisuke Miyamori +2 more
wiley +1 more source
Review Article - Biological agents in rheumatoid arthritis
, 2004 Rheumatoid arthritis (RA) is the commonest inflammatory joint disease with considerable morbidity and mortality. Conventional disease-modifying antirheumatic drugs like methotrexate form the cornerstone of therapy.
Shankar S, Handa Rohini
core +1 more source
Nursing Open, Volume 13, Issue 6, June 2026.ABSTRACT Aim The present study aimed to adapt into Turkish the Morning Stiffness Assessment Scale for Patients with Rheumatoid Arthritis, developed in 2021, and to examine the validity and reliability of the Turkish version. Design The study was conducted with a methodological design.
Gülcan Bahçecioğlu Turan +2 more
wiley +1 more source
Pharmacoepidemiology and Drug Safety, Volume 35, Issue 6, June 2026.ABSTRACT Purpose Janus kinase inhibitors (JAKi) are medicines used to treat inflammatory rheumatic musculoskeletal diseases (IRMDs) and inflammatory bowel diseases (IBDs). In Europe, JAKis received marketing authorisation in 2017 for rheumatoid arthritis.
Jarno Rutanen +3 more
wiley +1 more source
Научно-практическая ревматология, 2016 Despite major advances in the management of rheumatoid arthritis (RA), whicare associated with the development of new methods for its early diagnosis, the clinical introduction of a wide range of innovative medications and particularly the improvement of
E. L. Nasonov
doaj
Pharmacoepidemiology and Drug Safety, Volume 35, Issue 6, June 2026.ABSTRACT Background Direct oral anticoagulants (DOACs) offer advantages over warfarin; however, concerns exist regarding their association with acute interstitial lung diseases (ILDs). This study investigated the risk of acute‐onset ILDs associated with DOAC use.
Keisuke Anan +5 more
wiley +1 more source
Disease-modifying antirheumatic drug therapy for psoriatic arthritis
, 2002 As erosive and deforming arthritis is present in 40% of patients with psoriatic arthritis (PsA), early and aggressive treatment with disease-modifying antirheumatic drugs (DMARDs) may be as effective in controlling the progression of the disease as it is
Cantini, F +2 more
core